Oncology News

Circulating microRNAs may be used as noninvasive markers for predicting risk for developing hepatocellular carcinoma in patients with hepatitis B virus infection, according to recently published findings.

CHICAGO — Liquid biopsy identified genomic alterations in patients with advanced solid tumors at a similar rate to traditional tumor biopsy, according to data presented at the ASCO Annual Meeting.

The overall survival and safety rates were similar between patients with advanced hepatocellular carcinoma treated with Dovitinib vs. Nexavar, according to published findings.

Leisure-time physical activity was associated with lower risks for 13 out of 26 cancers included in an investigation published in JAMA Internal Medicine.

Nucleos(t)ide analogues for hepatitis B virus infection decreased a patient’s risk for infection-related hepatocellular carcinoma after curative therapy with radiofrequency ablation, according to published findings.

Alcohol consumption — including light-to-moderate — was associated with an increased risk for hepatocellular carcinoma among patients with hepatitis C virus infection-related cirrhosis, according to published findings.

SAN DIEGO — When compared to wild-type RAS, mutant RAS colorectal liver metastases recurred earlier and had worse overall survival after repeat hepatectomy, pointing toward the importance of knowing RAS mutation status, according to data presented at DDW 2016.

In partnership with DDW, Healio Gastroenterology brings you physician research from the investigators themselves. Here, Fabio Bagante, MD, discusses a new nomogram for neuroendocrine liver metastasis.

SAN DIEGO —  Non-white patients with hepatocellular carcinoma were less likely to undergo curative therapy and more likely to experience therapeutic delays than white patients, according to findings presented at Digestive Disease Week 2016.

In a new study, Medicare beneficiaries with advanced hepatocellular carcinoma treated with Nexavar only had a median survival of 3 months.